Jeff Hansen

Jeff Hansen

| This email address is being protected from spambots. You need JavaScript enabled to view it.

Research Editor

jeffhans@uab.edu • (205) 209-2355

Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.

Specific beats include: biochemistry; cell, developmental and integrated biology; microbiology; molecular genetics; neurobiology; pathology; pharmacology and tocixology; Alabama Drug Discovery Alliance; Bill L. Harbert Institute for Innovation and Entrepreneurship.

UAB's strengths in clinical care and research are powering an interdisciplinary expedition into largely uncharted territory: neuroinflammatory mechanisms in Parkinson's disease.
E. coli ClpB is a bacterial enzyme that untangles proteins. Such tangles are hallmarks of neurodegenerative diseases like Parkinson’s and Alzheimer’s. A study led by UAB's Aaron Lucius, Ph.D., offers new insight on this amazing molecular machine, and could eventually point toward new treatment approaches.
UAB researchers discover a new protein interaction from the 1918 flu strain that may help influenza circumvent the host immune response that would fight viral infection.
Famed neuroscientist Roger Nicoll, Ph.D., recently came to UAB to explain how he prevailed over great challenges in his life. Grad students in UAB’s Neuroscience Roadmap Scholars Program appreciated that, because they face challenges too. Learn about Nicoll’s tear-inducing speech, and the groundbreaking Roadmap program for underrepresented students, in The Mix.
An Arizona drug company will patent the small peptide drug.
Until now, no toxin had been found in 132 years of study for the deadly pathogen Mycobacterium tuberculosis, which infects 9 million people a year and kills more than 1 million. The novel toxin induces necrotic cell death of macrophages to help the tuberculosis pathogen escape and spread to other cells.
The challenge is to stifle the binding of inhibitory antibodies but retain activity of a blood enzyme.
The mimicry of bone cells by multiple myeloma is driven by overexpression of Runx2, the master regulator of bone formation.
The drug inhibits the activity of a kinase enzyme called LRRK2, and it showed no pathology in rat lungs, kidneys or livers.
Best of 2015 2The intensive intervention was four hours a day, five days a week, for a total of 200 hours of face-to-face instruction, and neuroimaging revealed brain connectivity changes.
Page 19 of 22